Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on London's AIM board (RENX). At pricing, the company...read more
Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, announced terms for its IPO on Monday. The Cardiff, United Kingdom-based company plans to raise $78 million by offering 5.5 million ADSs at $14.22, the as-converted last...read more
US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week
Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
US IPO Weekly Recap: nCino pops 195% in 8 IPO week
Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which ...read more
Kidney diagnostics developer Renalytix AI prices US IPO at $13.50
Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on London's AIM board (RENX). At pricing, the company...read more
Kidney diagnostics developer Renalytix AI sets terms for $78 million US IPO
Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, announced terms for its IPO on Monday. The Cardiff, United Kingdom-based company plans to raise $78 million by offering 5.5 million ADSs at $14.22, the as-converted last...read more